

## PATENT

Sir:

5. The '492 Application provides the first teaching in the art that the concentrations of the genomic sequences of HPV types 16 and 31 must be lowered relative to the concentrations of the genomic sequences of HPV types 18, 33, 35, and 51 in order to eliminate undesired cross-reactivity with the genomic sequence of HPV types 42, 43, or 44.

6. A researcher in the field of gynecological pathology who has read the '492 Application would understand that the suitable reagents (*i.e.*, reagents that do not cross-react with the genomic sequence of HPV types 42, 43, or 44) could be prepared by modifying the concentrations of the genomic DNA probes specified in Table 2 of the '492 Application.

7. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signed: Gerard J. Nuovo  
Gerard J. Nuovo

Dated: 11/11/07